MEMSCAP Pivots to Aerospace as Medical Sales Plummet in Mixed 2025

GRENOBLE, France – March 25, 2026 – MEMSCAP, a specialist in high-precision micro-electromechanical systems (MEMS), today reported a complex financial picture for its 2025 fiscal year. While consolidated revenue saw a 5.3% decline to €11.99 million, the company demonstrated a significant strategic shift, with its aerospace division soaring to become the dominant engine of growth and profitability.

The results paint a portrait of a company in transition, weathering a severe downturn in its medical business while doubling down on its strengths in the high-barrier aerospace market. Despite the top-line contraction and a drop in net profit to €894,000 from €1.37 million in 2024, MEMSCAP improved its gross margin, grew its cash reserves, and announced a new dividend, signaling confidence in its realigned strategy.

Aerospace Becomes the Core Growth Engine

The standout success story in MEMSCAP's 2025 report is the robust performance of its aerospace division. Revenue from this segment climbed 7.5% to reach €8.81 million, now accounting for a commanding 73.5% of the group's total sales, up from 64.7% the previous year. The company attributes this "strong growth momentum" to the development of its "Engine control" and "Fluidic systems" programs.

This performance aligns with powerful trends across the aerospace industry. The global market for aircraft engine control systems is on an optimistic trajectory, with projections suggesting it could grow from $5 billion to $9 billion by 2033. This demand is fueled by a drive for greater fuel efficiency, reduced operational costs, and stricter environmental regulations. Similarly, the market for aircraft environmental control systems is forecasted to reach USD 5.25 billion by 2030. MEMSCAP's high-accuracy, high-stability pressure sensors are critical components in these sophisticated systems.

The aerospace sector is notoriously difficult to enter, with stringent qualification standards like DO-254 and DO-160 creating significant technological and regulatory barriers. This environment protects established players like MEMSCAP, allowing them to secure long-term positions on next-generation aircraft programs. The company's focus on this high-value segment is not just a defensive move but a strategic offensive to capture growth in a market where its technological expertise provides a durable competitive advantage.

Medical Segment Faces Customer Concentration Headwinds

In stark contrast to the success in aerospace, MEMSCAP's medical activities experienced a precipitous decline. The segment's revenue fell by 53.2% to just €1.47 million, a sharp drop from €3.15 million in 2024. The company was direct about the cause, attributing the €1.65 million revenue impact to a "decrease in orders from two major long-standing customers."

This highlights a significant risk of customer concentration. While the broader market for MEMS in medical applications is expanding—driven by the growth of wearable devices, point-of-care diagnostics, and minimally invasive procedures—reliance on a small number of large clients left the segment vulnerable. The sudden reduction in orders underscores the challenges companies can face even within a thriving industry if their customer base is not sufficiently diversified.

In response, MEMSCAP appears to be re-evaluating its resource allocation. While the company stated that R&D expenses included the "development of new generations of... medical products," the dramatic revenue shift suggests that aerospace will command the lion's share of its strategic focus for the foreseeable future.

A Picture of Financial Prudence and Shareholder Return

Despite the revenue challenges, MEMSCAP's underlying financial health appears solid, reflecting disciplined operational management. A key indicator is the improvement in gross margin, which rose to 41.4% from 39.7% in 2024. The company credited this to a "favourable product mix," a direct result of the increasing share of high-margin aerospace sales offsetting the decline in other areas.

Furthermore, the company's balance sheet has strengthened. Available cash grew to €6.04 million, and the group reported no financial borrowings, resulting in a strong net cash position. This financial stability has enabled the board to propose a dividend of €0.066 per share, a move described as an "important milestone" in its shareholder return policy. For a company that has not consistently paid dividends, this new policy signals strong confidence from management in its long-term cash flow and profitability.

The company also streamlined its operations, reducing its average full-time equivalent workforce by 9.1%. This was not a blanket cut but part of a strategic reorganization. Expenses for the sales team were reduced by 12.3%, while R&D spending, net of subsidies, increased to 13.2% of consolidated revenue, up from 11.3% in 2024. This deliberate reallocation of resources away from sales overhead and toward innovation underscores the company's commitment to strengthening its technological leadership in its core markets.

Navigating Niche Markets with a Flexible Model

Beyond its two largest segments, MEMSCAP's optical communications division also posted impressive growth, with revenue increasing by 31.4% to €1.63 million. The company notes this market is characterized by "high volatility linked to fiber optic investment cycles in Asia," particularly China. Global demand for fiber optics is surging due to 5G rollouts and data center expansion, with the Asia-Pacific region leading the charge.

To navigate this volatility, MEMSCAP employs a "fabless operating model" for this division, outsourcing manufacturing while focusing on design and marketing. This strategy allows the company to capitalize on market upswings without the heavy capital expenditure and risk associated with owning and operating its own fabrication facilities, ensuring the division "supports the Group’s profitability, regardless of activity levels."

This combination of deep investment in the high-barrier aerospace market, a cautious but ongoing R&D effort in medical, and a flexible, low-capital approach to the volatile optical communications market illustrates a multi-faceted strategy. By focusing on its core technological strengths and maintaining financial discipline, MEMSCAP is positioning itself to leverage its dominance in aerospace as the primary driver for future performance and profitability.